HCW Biologics regains Nasdaq bid price compliance, plans reverse split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St set for lower open as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026 8:25 AM EDTCompany now compliant with all continued listing rules for Nasdaq
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the Panel) of The Nasdaq Stock Market LLC (Nasdaq or the Exchange) found that the Company regained compliance with Listing Rule 5550(a)(2), the Bid Price... More
